Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.
Cazorla
M
M
Laboratory of Neurobiology & Molecular Pharmacology, Centre de Psychiatrie et Neurosciences, UMR-894 INSERM/Université Paris Descartes, 2Ter rue d'Alésia, Paris, France. mc3195@columbia.edu
Arrang
J M
JM
Prémont
J
J
D000494:Allosteric Regulation; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D000918:Antibody Specificity; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D016466:CHO Cells; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology; D006224:Cricetinae; D003412:Cricetulus; D004622:Embryo, Mammalian; D006801:Humans; D051379:Mice; D016501:Neurites / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D016716:PC12 Cells; D051381:Rats; D020813:Receptor, trkB / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D000906:Antibodies; D000911:Antibodies, Monoclonal; D019208:Brain-Derived Neurotrophic Factor; D011993:Recombinant Fusion Proteins; D020813:Receptor, trkB